Introduction
Angioimmunoblastic lymphadenopathy with dysproteinemia (AILD)' is a potentially fatal disorder ofuncertain etiology characterized by generalized lymphadenopathy, hepatosplenomegaly, skin rash, polyclonal hypergammaglobulinemia, and hemolytic anemia (1) (2) (3) . Despite the lymphomalike clinical syndrome, the histological picture is often more consistent with a benign polymorphous immunoproliferative disorder (4) . Indeed, in some patients, the disease may remain indolent or even regress in the absence of cytotoxic therapy (2) . However, in the majority of patients the disease pursues an aggressive course, leading to death in 75% of the cases and a median survival of 30 mo (5) .
The most serious complication of AILD is the development of an aggressive (immunoblastic) non-Hodgkin's lymphoma, which occurs in nearly half of all patients (4). It is not known if AILD is neoplastic at onset, and the relationship between AILD and subsequent lymphoma has been difficult to define. Tissues involved by AILD contain mixtures of T and B lymphocytes (6) , whereas lymphomas arising in AILD have been variously described as poly-or monoclonal B-cell type (7) (8) (9) (10) or T-cell type (1 1) . Cells from lymph nodes containing both AILD and lymphoma demonstrate cytogenetic abnormalities (12) , but it is not known whether these abnormalities occur in the malignant lymphoma cells or are in cells of B or T lineage.
To help resolve questions concerning the cellular derivation and clonality ofAILD and its associated malignant lymphomas, we performed gene rearrangement analysis on patient material. As previously demonstrated, detection of rearranged genes by Southern blot analysis can reveal cellular lineage and clonality in lymphoid neoplasms (.13-19) . In this study we have subjected tissues from patients with AILD and other forms of lymphoid hyperplasia to Southern blot analysis, using probes that detect gene rearrangements characteristic of either B cells (immunoglobulin genes) ( 14, 15) or T cells (T-cell receptor ,-chain gene) (16) (17) (18) to determine both lineage and clonality. With this approach we now provide evidence that AILD is a disease of proliferating lymphoid clones, in which supervening malignant lymphomas may develop by a process of clonal selection.
Methods
Patient samples. All patients were seen at the National Institutes ofHealth and each presented with the typical clinical and laboratory features of AILD, including generalized lymphadenopathy, skin rash, polyclonal gammopathy, and classic histologic features of AILD (4) in lymph node specimens. A chronology of specimens and their diagnoses obtained from each patient during the course of disease is presented in Table I . Lymph nodes containing other forms of lymphoid hyperplasia were obtained for comparison. Histological diagnoses in these 11 cases included follicular hyperplasia (six cases), mixed follicular and paracortical hyperplasia (two cases), and atypical lymphoid hyperplasia (three cases). Underlying diseases in these patients included hypereosinophilic syndrome, common variable hypogammaglobulinemia, rheumatoid arthritis, AIDS-related complex with persistent lymphadenopathy, and Hodgkin's disease. In addition, peripheral blood mononuclear cell DNA from three normal donors was examined.
DNA analysis. High-molecular-weight genomic DNA was extracted from the lymph nodes and peripheral blood by standard methods. DNA was digested with appropriate restriction endonucleases, size separated by electrophoresis on 0.8% agarose gels, transferred onto nylon membranes (GeneScreen Plus, New England Nuclear, Boston, MA) by the method of Southern (20), and hybridized with 32P-radiolabeled DNA probes (21), as previously described ( 14, 21) . Probes included a constant region-specific, A vaI/Pstl fragment ofthe human T-cell receptor (-chain cDNA clone YT35 (22) , and human genomic JH, C,, JX, and C, immunoglobulin gene probes, as reported (14) . Rearrangements were conClonality ofAngioimmunoblastic Lymphadenopathy 637 (Table I) . Rearrangements were found in lymph nodes from each patient studied and in the peripheral blood of four of five patients.
In patient 1, a single immunoglobulin heavy-chain gene rearrangement and a single T-cell receptor ,3-chain gene rearrangement persisted in all three specimens (Fig. 2) . Coincident with histological progression to malignant lymphoma (sample 1c) was the appearance of additional immunoglobulin gene rearrangements involving a second heavy-chain allele and two lambda light-chain alleles. The new heavy-and light-chain gene rearrangements in specimen 1c are most consistent with the emergence of a clonal B-cell lymphoma in this lymph node.
Of the four specimens analyzed from patient 2, rearrangements were found in two lymph node biopsies exhibiting AILD (samples 2b and 2c). However, the gene rearrangements were different between these samples since only a T(3 rearrangement was seen in sample 2b (not shown) but a single Ig, gene rearrangement was found in 2c ( Fig. 3) Table I ) show consistent T-cell receptor 13 Of the two peripheral blood samples available from patient 3, the earlier one, 3a, contained both an immunoglobulin gene rearrangement (IgK) and a T cell receptor gene rearrangement (TB) in the same specimen (Fig. 3) . By (Fig. 3) .
Sequential sampling ofpatient 4 revealed a single rearranged IgH allele in the first peripheral blood specimen (4a) and no evidence of rearrangements in the second peripheral blood sample (4b). A lymph node with the morphological features of AILD (4c) contained two rearranged T13 alleles (Fig. 3) (7, 10) . Direct analysis of the clonality of the T-cell population could not be readily performed until recently, following the discovery and application of probes for the rearranging T-cell receptor i-chain gene (22) . The advent of gene rearrangement analysis, using a combination of immunoglobulin and T-cell receptor gene probes, offers the opportunity to address questions regarding clonality and lineage of enigmatic lymphoid hyperplasias such as AILD.
In the present study, we have discovered clonal lymphoid populations in the peripheral blood and lymph nodes of five patients with typical clinical and laboratory findings of AILD. This result indicates that AILD is a lymphoproliferative process in which clones of B cells, T cells, or both, expand during the course of disease and infiltrate lymph nodes as well as the peripheral circulation. One may detect rearrangements of either immunoglobulin or T-cell receptor genes. Clonal expansion of both B and T cells suggests that AILD may be a disorder of a b c d e f g h a immunoregulation, in which lymphoid cells are permitted to proliferate in great excess. In contrast to AILD, other forms of lymphoid hyperplasia were not found to contain detectable lymphoid clones. Presumably, in most forms ofhyperplasia, immunoregulatory controls remain intact and no individual lymphoid clone can expand to a threshold level detectable by Southern blot analysis. The etiology of the immunoregulatory defect in AILD is unknown, but it is possible that antigenic stimulation triggers lymphoid proliferation in these patients. For example, AILD has been associated with hypersensitivity reactions to drugs to other exogenous substances (26) (27) (28) . An infectious organism, such as a virus, might selectively stimulate or destroy immunoregulatory subsets, leading to deregulation ofthe immune response. Consistent with this hypothesis, T cells from some patients produce factors which induce immunoblastic transformation of B cells (29) .
Because of their propensity to disappear or not progress to overt malignant lymphoma, the proliferating lymphoid clones in AILD might not be malignant neoplasms at onset. However, expanding clones would be susceptible to genetic errors during the repeating cell division process. For example, a chromosomal translocation could result in constitutive activation ofa growthpromoting substance, perhaps encoded by an oncogene, as has been suggested for a number ofhematopoietic malignancies (30) . Such an activation ofthe cellular oncogene c-myb has been previously reported in patient 2 from this series (31) . It is hypothesized by analogy that Burkitt's lymphoma arises in a setting of chronic Epstein-Barr virus stimulation, in which B cells undergoing repeated rounds of cell division are at risk of a chromosomal translocation involving the c-myc oncogene and one of the immunoglobulin genes (32, 33) . Likewise, it appears that in AILD a secondary event or events must occur to produce malignant transformation and selective proliferation of the malignant clone. Although we did not perform cytogenetic studies that might identify accumulated chromosomal abnormalities during disease progression, patterns of clonal selection similar to those reported here are suggested by previous cytogenetic studies in AILD (12) . The (35) . Many of these are probably B-cell clones infected by Epstein-Barr virus, a B-cell mitogen, and they frequently regress upon reduction or cessation of immunosuppressive therapy (36); therefore, they are best regarded as poorly regulated B-cell clones.
Molecular genetic analysis of human lymphoproliferative disease has provided evidence for the clonality and cellular origin of a number of disorders such as common acute lymphoblastic leukemia and hairy cell leukemia (13, 37) . This demonstrates their monoclonality and cellular lineage simultaneously without the necessity of gene expression. For example, immunophenotypic analysis of the present cases revealed no evidence of clonality despite the detection of lymphoid clones by genetic hybridization. Furthermore, as no readily available phenotypic marker of T-cell clonality exists, clonality as determined by Tcell gene rearrangement analysis has effectively assumed a preeminent role in the diagnosis and classification of T-cell disorders (16) (17) (18) (19) 23) . With this technology, we have explored questions regarding the origin of AILD and its associated malignant lymphoma. This methodology should be generally helpful in the diagnosis of AILD and in investigations to determine its etiology.
